Navigation Links
InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
Date:10/28/2008

BRITISH COLUMBIA, Canada, Oct. 28 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that Jeff Morhet, CEO and Chairman, will present at the 7th Annual BIO Investor Forum on October 30, 2008.

Mr. Morhet's thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform, recent partnerships and company milestones.

The 7th Annual BIO Investor Forum will be held October 29-31, 2008 at the Palace Hotel in San Francisco, California. The BIO Investor Forum is held every year to bring late-stage private and emerging public biotech companies and investors together to meet and attend roundtables, panel discussions and seminars on a variety of biotechnology topics.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. InNexus Biotechnology Strengthens Patent Team With New Leadership
5. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
9. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
10. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
11. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City and Center ... of Community and Economic Development in 2016 as part of the Keystone Innovation Zone ... Keystone Innovation Zone and represent the highest number of awards to the largest number ...
(Date:1/18/2017)... PUNE, India , Jan. 18, 2017  Market Research Future ... Cancer Diagnostics Market is expected to grow at a CAGR of ... Highlights ... a disease caused due to the abnormal cell division without any ... and cause harm to them. These cancer cells can spread to ...
(Date:1/17/2017)... 17, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA ... for the detection of foodborne pathogens today announced the appointment of ... Paul Thomas , the Company,s President and CEO since 2009, ... of Directors.  The changes are effective today. In addition, ... ...
(Date:1/17/2017)... -- Only nine percent of U.S. consumers believe pharmaceutical and ... percent believe health insurance companies do, according to a ... U.S. adults believe health care providers (such as doctors ... (23%). "We are in the midst of ... vice president of reputation management and public affairs at ...
Breaking Biology Technology:
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
Breaking Biology News(10 mins):